Acadian Asset Management’s Repare Therapeutics RPTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-618,672
| Closed | -$1.61M | – | 2222 |
|
|
2025
Q4 | $1.61M | Buy |
618,672
+50,371
| +9% | +$101K | ﹤0.01% | 979 |
|
|
2025
Q3 | $996K | Sell |
568,301
-112,879
| -17% | -$181K | ﹤0.01% | 1055 |
|
|
2025
Q2 | $942K | Buy |
681,180
+40,848
| +6% | +$53.3K | ﹤0.01% | 993 |
|
|
2025
Q1 | $624K | Buy |
640,332
+168,230
| +36% | +$203K | ﹤0.01% | 1037 |
|
|
2024
Q4 | $613K | Buy |
472,102
+24,509
| +5% | +$73K | ﹤0.01% | 1034 |
|
|
2024
Q3 | $1.54M | Buy |
447,593
+29,664
| +7% | +$97.7K | ﹤0.01% | 816 |
|
|
2024
Q2 | $1.37M | Buy |
417,929
+284,036
| +212% | +$1.01M | ﹤0.01% | 891 |
|
|
2024
Q1 | $625K | Buy |
133,893
+46,648
| +53% | +$299K | ﹤0.01% | 956 |
|
|
2023
Q4 | $634K | Buy |
87,245
+5,616
| +7% | +$31.4K | ﹤0.01% | 971 |
|
|
2023
Q3 | $984K | Hold |
81,629
| – | – | ﹤0.01% | 856 |
|
|
2023
Q2 | $860K | Sell |
81,629
-2,644
| -3% | -$27.2K | ﹤0.01% | 918 |
|
|
2023
Q1 | $826K | Buy |
84,273
+58,108
| +222% | +$667K | ﹤0.01% | 926 |
|
|
2022
Q4 | $384K | Buy |
+26,165
| New | +$391K | ﹤0.01% | 1115 |
|
Acadian Asset Management's RPTX Position: Q1 2026 in Review
Acadian Asset Management sold out of Repare Therapeutics (RPTX) in Q1 2026, closing a stake of 618,672 shares — an estimated $1.61M sold.
Acadian Asset Management first reported a position in RPTX in Q4 2022 and held it in 13 quarters. The position peaked at $1.61M in Q4 2025. 0 funds tracked by Wall St. Rank hold RPTX as of Q1 2026.
- Acadian Asset Management reported no remaining Repare Therapeutics position as of Q1 2026 after selling out during the quarter.
- Acadian Asset Management sold 618,672 Repare Therapeutics shares in Q1 2026, an estimated $1.61M.
- Acadian Asset Management first reported a position in Repare Therapeutics in Q4 2022 and held it in 13 quarters.
- Acadian Asset Management's Repare Therapeutics position peaked at $1.61M in Q4 2025.
- 0 funds tracked by Wall St. Rank held Repare Therapeutics as of Q1 2026.
Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.